Get started
Author

I. Kim

Comparative Efficacy of Biologics in Psoriasis
2012 · Iris H. Kim, Cameron E. West, et al. · American Journal of Clinical Dermatology · 63
Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG)
2021 · H.S. Park, B. Kang, et al. · ESMO Open · 40
PDF
Differential Impact of Smoking on Methylome and Transcriptome in Crohn’s Disease and Ulcerative Colitis
2023 · Qi Yan Ang, Damian Plichta, et al. · Inflammatory Bowel Diseases · 13
PDF
970P Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries
2023 · C-K. Lee, C. Yoo, et al. · Annals of Oncology · 3
PDF
Inborn Errors of Immunity in Apoptosis
2025 · Nadia Makkoukdji, Travis Satnarine, et al. · Frontiers in Bioscience-Landmark · 2
PDF
OP02-3 Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior atezolizumab and bevacizumab treatment: A multicenter retrospective study
2025 · J.S. Kim, B. Kang, et al. · ESMO Open · 2
PDF
955P Prognostic factor analysis of atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: Korean cancer study group (KCSG) study
2021 · J. Cheon, C. Yoo, et al. · Annals of Oncology · 2
PDF
946P Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior atezolizumab and bevacizumab treatment: A multicenter retrospective study
2024 · J.S. Kim, B. Kang, et al. · Annals of Oncology · 1
PDF
Association of polycystic ovary syndrome with atopic dermatitis: a case control study
2024 · Iris H. Kim, Luis F. Andrade, et al. · Archives of Dermatological Research · 1
Social Media Misconceptions About Topical Minoxidil: A Mixed‐Methods Evaluation of Perceived Versus Reported Adverse Effects
2025 · Tanya Boghosian, Olivia M. Burke, et al. · International Journal of Dermatology
1490P Infiltrative HCC defines a clinically and molecularly distinct subtype with poor clinical outcomes from atezolizumab plus bevacizumab
2025 · H.J. Chon, W.S. Lee, et al. · Annals of Oncology
2071P Identification of top issues and concerns of cancer patients in Korea on social media
2023 · J.H. Lim, D. Kim, et al. · Annals of Oncology
PDF
221P Peripheral T cell activation phenotype predicts clinical outcomes of atezolizumab-bevacizumab therapy in unresectable hepatocellular carcinoma
2023 · C. Kim, W.S. Lee, et al. · Annals of Oncology
PDF
218P Peripheral T cell activation phenotype is associated with clinical outcomes and immune-related adverse events of ipilimumab-nivolumab in advanced hepatocellular carcinoma
2023 · W.S. Lee, H. Yang, et al. · Annals of Oncology
PDF
993P Thyroid dysfunction after atezolizumab and bevacizumab is associated with favorable outcomes in hepatocellular carcinoma (IMbrave150 and Korean patients cohorts)
2023 · H. Chon, Y.S. Song, et al. · Annals of Oncology
PDF
103P Individual patient data (IPD) meta-analysis of randomised trials to compare efficacy of second-line fluoropyrimidine-based chemotherapy in advanced biliary tract cancer (BTC)
2023 · J. Hyung, M. Kang, et al. · Annals of Oncology
PDF
952P Prognostic implication of serum alpha-fetoprotein in patients with unresectable hepatocellular carcinoma treated with regorafenib
2021 · D-H. Lim, A. Casadei-Gardini, et al. · Annals of Oncology
PDF
Acral melanoma in the Asian/Pacific Islander population: Analysis of +8q and 8q24 chromosomal aberrations.
2013 · Shane Young Morita, Iris H. Kim, et al. · Journal of Clinical Oncology
Works count: 18
Citation count: 127
H-index: 3
I10-index: 3
Year
Topic
Type